Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Urinary Bladder Neoplasms 6 Non-Muscle Invasive Bladder Neoplasms 5 Glioma 4 Carcinoma, Transitional Cell 3 Wilms Tumor 2 Urothelial Cancer 2 Rhabdoid Tumor 2 Prostatic Neoplasms 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Multiple Myeloma 2 Medulloblastoma 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Ependymoma 2 Central Nervous System Neoplasms 2 Xanthogranuloma, Juvenile 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1

Interventions

Injections 13 pembrolizumab 10 tislelizumab 9 toripalimab 6 atezolizumab 4 Nivolumab 4 Carboplatin 3 trastuzumab deruxtecan 2 olaparib 2 lenvatinib 2 Pemetrexed 2 Paclitaxel 2 Oxaliplatin 2 Gemcitabine 2 Fluorouracil 2 Docetaxel 2 Cyclophosphamide 2 Cisplatin 2 Cetuximab 2 Bevacizumab 2 zimberelimab 1 talazoparib 1 spartalizumab 1 sotorasib 1 serabelisib 1 penpulimab 1 niraparib 1 nedaplatin 1 mirdametinib 1 fludarabine phosphate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Solid Tumor × erdafitinib × 1 year × Clear all

NCT04083976 2026-05-04

RAGNAR

Janssen Research & Development, LLC

Phase 2 Completed

316 enrolled 15 charts

Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡